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Background: In the last decade, a disorder characterized by episodes of involuntary movements and dystonia has been
recognized in Border Terriers.
Objectives: To define clinical features of paroxysmal dyskinesia (PD) in a large number of Border Terriers and to study
the genetics of the disease.
Animals: 110 affected and 128 unaffected client-owned Border Terriers.
Methods: A questionnaire regarding clinical characteristics of PD was designed at Utrecht University and the University
of Helsinki. Thirty-five affected Border Terriers underwent physical examination and blood testing (hematology and clinical
biochemistry). Diagnostic imaging of the brain was performed in 17 affected dogs and electroencephalograms (EEG) between
episodes were obtained in 10 affected dogs. A genomewide association study (GWAS) was performed with DNA of 110
affected and 128 unaffected dogs.
Results: One hundred forty-seven questionnaires were included in the study. The most characteristic signs during episodes
were dystonia, muscle fasciculations, and falling over. The majority of owners believed that their dogs remained conscious
during the episodes. A beneficial effect of anti-epileptic therapy was observed in 29 of 43 dogs. Fifteen owners changed their
dogs’ diet to a hypoallergenic, gluten-free diet, and all reported reasonable to good improvement of signs. Clinical examina-
tions and diagnostic test results were unremarkable. The GWAS did not identify significantly associated chromosome
regions.
Conclusions and Clinical Importance: The survey results and EEG studies provided further evidence that the observed
syndrome is a PD rather than epilepsy. Failure to achieve conclusive results by GWAS indicates that inheritance of PD in
Border Terriers probably is complex.
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Paroxysmal dyskinesias (PDs) are rare movementdisorders characterized by recurrent episodes of
involuntary hyperkinetic movements, altered muscle
tone and a variable phenotype. A key feature is pre-
served consciousness during the attacks. Based on trig-
gering events, frequency, duration, and characteristics
of the hyperkinetic episodes, 3 distinct types of PDs are
recognized in human medicine: (1) paroxysmal kinesi-
genic dyskinesia (PKD) in which the attacks are
induced by abrupt voluntary movements, (2) paroxys-
mal nonkinesigenic dyskinesia (PNKD) in which the
attacks are not preceded by sudden movement or exer-
cise, and (3) paroxysmal exertion-induced dyskinesia
(PED) in which attacks are triggered by prolonged
physical exercise.1,2 All forms can be primary with a
suspected or known genetic etiology or secondary to
other disorders such as multiple sclerosis and head
trauma.1,3 In the last decade, causative mutations in the
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CECS canine epileptoid cramping syndrome
CT computed tomography
EEG electroencephalography
GWAS genomewide association study
MRI magnetic resonance imaging
PD paroxysmal dyskinesia
PED paroxysmal exertion-induced dyskinesia
PKD paroxysmal kinesigenic dyskinesia
PNKD paroxysmal nonkinesigenic dyskinesia
SNP single nucleotide polymorphism
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following genes have been identified for all of the
above-mentioned types: PRRT2 for PKD, PNKD (MR-
1) and KCNMA1 for PNKD, and SLC2A1 (GLUT1)
for PED.4–7
Initially, PDs (and especially PKD) were regarded as a
type of focal epilepsy based on brief paroxysmal attacks,
frequent premonitory sensations, and dramatic positive
response to anti-epileptic drugs in PKD. However, over
the last few decades, many authors favor the hypothesis
that they represent nonepileptic movement disorders
because of normal interictal and ictal electroencephalog-
raphy (EEG) findings in most patients, maintained con-
sciousness and the absence of a post-ictal phase.8,9
Paroxysmal dyskinesias are increasingly recognized in
dogs. Both sporadic and familial cases of (suspected)
paroxysmal dyskinesia have been reported.10–13 A dele-
tion in the BCAN gene was identified as the cause of
Episodic Falling Syndrome, a paroxysmal hypertonicity
disorder, in Cavalier King Charles Spaniels.14,15
Recently, phenotypic characteristics of a suspected
paroxysmal dyskinesia, referred to as canine epileptoid
cramping syndrome (CECS), were described in 29 Bor-
der Terriers in which clinical features resembled
PNKD.16 However, no EEG studies were performed. In
the past decade, “cramping episodes” also have been
reported by breeders and owners of specific families of
Border Terriers in the Netherlands and Germany. Dur-
ing the same time frame, an increasing number of Bor-
der Terriers with episodic dystonia was observed in
Finland. Clinical and genetic investigations were begun
at the Veterinary Faculty of the University of Helsinki
(Finland) and the Utrecht University (the Netherlands).
Correct phenotyping is essential for genetic studies,
but can be challenging in paroxysmal disorders with nor-
mal presentation between episodes, variable clinical pre-
sentation, and unknown pathophysiology. The goal of
our study was to thoroughly characterize clinical signs in
a large number of affected Border Terriers, describe diag-
nostic features (including EEG findings), establish preva-
lence, and investigate genetic aspects of “cramping
episodes” in Border Terriers. For this purpose, results
from Dutch and Finnish studies were combined.
Materials and Methods
Prevalence Studies
A general health surveillance survey in a cohort of Border Ter-
riers was initiated by the Dutch Border Terrier club in 2004. A
comprehensive questionnaire concerning health and behavior was
designed and sent to owners of 1126 Dutch Border Terriers born
between 1998 and 2001. One of the questions was whether the dog
had experienced episodes of abnormal movements or posture. Five
years later, the study was repeated and owners of 1494 Dutch Bor-
der Terriers born between 2003 and 2006 were invited to complete
the survey. The results of the general health surveillances were
used to estimate the prevalence of PD.
Questionnaire on PD
In the Netherlands and Finland, an extensive questionnaire on
PD was developed. Because the 2 surveys were designed indepen-
dently, they were not identical. However, both surveyed sex, age
of onset, episode characteristics, signs immediately before and
after episodes, possible predisposing factors, and average number
and duration of episodes. Information on medical history, treat-
ment, and diet also was collected. The Dutch questionnaire dif-
fered from the Finnish questionnaire in that it also requested
owners to judge the effect of medical treatment or dietary change
as none, moderate, reasonable, or good. In cases in which a rea-
sonable or good outcome was achieved, owners were asked
whether this outcome was the result of diminished frequency,
shorter duration of episodes, less severe clinical signs during the
episodes, or some combination of these.
Most questions had an “open” answer or a “do not know”
option after a list of possible answers in both questionnaires. Fur-
thermore, at the end of both questionnaires, respondents were
offered the possibility to give additional comments.
The Dutch questionnaire was distributed to 135 owners of sus-
pected affected Border Terriers from western Europe (the Nether-
lands and Germany). Suspected cases were recruited through the
Dutch Border Terrier Club and private veterinary practitioners.
Twenty-five western European Border Terriers were referred to the
Utrecht University Clinic for Companion Animals in the Nether-
lands, and the survey was conducted personally during the visit to
the clinic. The questionnaire also could be downloaded from sev-
eral relevant Internet sites. Owners of Border Terriers with episo-
dic abnormal movements or altered muscle tone were invited to
complete the online questionnaire. If answers in returned question-
naires were ambiguous, the responder was contacted by phone for
clarification. The Finnish questionnaires were collected following a
similar procedure. Seventy Finnish questionnaires were distributed
to owners of possible cases, recruited through the Breed Club and
veterinary practitioners.
Inclusion Criteria
Border Terriers were regarded as affected if they had experi-
enced ≥3 distinct episodes of abnormal movements or muscle tone
(eg, rigid extended limbs, back or neck, involuntary movements,
incoordination, or falling over) at least 2 weeks apart. Dogs with a
possible underlying cause (eg, head trauma, intoxication, heart dis-
ease) or neurological abnormalities between episodes were
excluded from the study.
The PD questionnaires from Border Terriers that met inclusion
criteria were used for statistical analysis of PD characteristics.
Clinical Studies
Twenty-five western European and 10 Finnish Border Terriers
that met the inclusion criteria underwent general physical and neu-
rological examinations and blood testing (CBC and biochemical
profile including potassium, sodium, calcium, phosphate, glucose,
urea, creatinine, alkaline phosphatase, alanine aminotransferase,
creatine kinase, total protein, and albumin) at the Neurology
Departments of the Companion Animal Clinics of the Universities
of Utrecht, the Netherlands and Helsinki, Finland. Additionally,
in the Finnish dogs, blood concentrations of triglycerides and
cholesterol were determined. In the western European patients,
fasting serum bile acid and ammonia concentrations also were
measured. Video recordings of episodes were available for 17 (17/
25) Border Terriers from western Europe.
Magnetic resonance imaging (MRI) of the brain was performed
in 7 western European affected Border Terriers (7/25) with an
open magnet 0.2-Tesla magnetic resonance unita with dogs in ster-
nal recumbency. Transverse T1-weighted, T2-weighted, and proton
density-weighted studies were obtained. After IV administration of
0.2 mL/kg contrast mediumb transverse T1, T1 FLASH 3D, sub-
traction, and dorsal FLAIR series also were acquired.
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Magnetic resonance imaging of the neurocranium of 3 (3/10)
affected Finnish Border Terriers was made with a 1.5 Tesla MRI
systemc (transverse and dorsal T2-weighted images and T1-
weighted 3D images before and after IV administration of
0.1 mmol/kg contrastd ). Additionally, multiplanar reconstructions
(MPR) in the sagittal, transverse, and dorsal planes were examined.
In the other 7 affected Finnish Border Terriers (7/10), contrast-
enhanced computed tomography (CT) scans of the brain were
made. Imaging was performed with a helical dual slice CT scan-
ner.e Images in 3 mm slice thickness were obtained before and
after administration of 2 mL/kg IV iodinated contrast medium.f
Electroencephalography was performed between episodes in all
examined affected Finnish Border Terriers (10/10) under medeto-
midineg sedation (0.04 mg/kg). Dogs that resisted needle place-
ment after 15 minutes of initial sedation received an additional
dose of medetomidine (0.02 mg/kg). Dogs were placed in sternal
recumbency, and SC needle electrodes were inserted over the cal-
varia. A 17-channel reference montage (F7, F3, Fz, F4, F8, T3,
C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, O2; reference, on the
nose; ground, caudal to the external occipital protuberance). The
total recording time was 20 minutes. Each EEG recording was
examined visually by an European College of Veterinary Neurol-
ogy board-certified veterinary neurologist. Additionally, an experi-
enced neurophysiologist evaluated the EEG data. Spikes and
sharp waves as well as focal abnormalities of the background were
registered. Evaluation of EEG recordings was not blinded.
Seven healthy control Finnish Border Terriers, recruited
through the breed club and private veterinary practitioners, under-
went the same diagnostic tests.
Pedigree Analysis
To identify families with a high prevalence and clarify a possi-
ble mode of inheritance, pedigrees of western European cases were
analyzed and combined when cases were related to other cases by
shared parents, grandparents, or great-grandparents. Pedigree data
of dogs participating in our research were used along with data
obtained from the Dutch Border Terrier Club and from the Dutch
Kennel Club to yield an extensive pedigree of approximately 350
Border Terriers going back 9 generations.
Information about the phenotype of the first 3 generations was
scarce. Breeders and owners were able to give information about
the phenotype of most of the dogs of recent generations. The phe-
notype of 134 dogs was established from the questionnaires on
PD. A similar pedigree was constructed for the affected Finnish
dogs.
Genetic Studies
For the genetic studies, inclusion criteria for cases were refined
to select “typical cramping cases” based on results of the PD ques-
tionnaires: Border Terriers were categorized as affected if they had
gone through ≥3 distinct episodes of involuntary abnormal move-
ments, altered muscle tone or both in their lifetime. Consciousness
had to be preserved during episodes and dystonia had to be a
prominent feature. Onset of the first episode had to be between 1
and 5 years of age, and episodes were considered distinct when
they occurred at least 2 weeks apart.
Owners of Border Terriers that met the strict inclusion criteria
for “typical cases” based on the results of the PD questionnaires
were asked to submit a blood sample from their dog for the
genetic studies.
Border Terriers were scored as unaffected if they were ≥7
years of age, and no episodes of abnormal movements or
behavior had ever been observed. Unaffected Border Terriers
were recruited through the Breed Clubs and private veterinary
practitioners. Blood samples from dogs that fulfilled the
inclusion criteria and unaffected control Border Terriers were
collected with the owners’ consent by veterinarians. The study
was approved by the Utrecht University Animal Experiments
Committee as required under Dutch legislation (Experiments on
Animals Act Wod. 2014, European Directive 2010/63/EU) and
the Animal Ethics Committee at the State Provincial Office
of Southern Finland (permit: ESAVI/6054/04.10.03/2012).
Genomic DNA was extracted from whole blood or buccal
swabs with QIAamp DNA Blood Midi Kit (QIAGEN), or salt
extraction.17
A genomewide association study (GWAS) was performed using
110 cases and 128 controls from the Border Terrier breed with the
Illumina CanineHD BeadChip array containing over 170,000 sin-
gle nucleotide polymorphisms (SNPs). The genotyped dogs origi-
nated from the western European (82 cases, 73 controls) and the
Finnish (28 cases, 55 controls) populations.
The SNPs passed quality control when the genotyping rate was
>90%, and the minimum allele frequency was >0.1. Individual
dogs had to be genotyped at >95% of the SNPs. The level of pop-
ulation stratification was assessed with GenABEL software gener-
ating a multidimensional scaling plot of principal components of
DNA data of individual cases and controls.18 Allele frequency dif-
ferences between the groups of cases and controls were evaluated
in R statistics package 3.0.2 with GenABEL.18,19 Population strati-
fication and cryptic relatedness in the sample were adjusted for by
mixed model analysis with genomic control implemented in the
function mmscore in GenABEL.20 A correction for multiple test-
ing consisted of 100,000 permutations of the phenotypes of the
sample.
Inbreeding coefficients were calculated for all cases and controls
with observed and expected numbers of homozygous genotypes,
based on the population of origin, by PLINK.21 To analyze
whether inbreeding coefficients were significantly different between




At the request of the Dutch Border Terrier club, 2
cohort studies on general characteristics, behavior, and
the prevalence of several health problems, including
neurological disorders, were conducted. In 2004, 670 of
1,126 (60%) and in 2009 918 of 1,494 (61%) question-
naires were completed and returned. In 2004, episodes
with abnormal movements or posture were most com-
mon with a prevalence of 7.6% in Border Terriers born
between 1998 and 2001. Five years later, the reported
prevalence of such episodes in Border Terriers born
between 2003 and 2006 was 4.8%.
Questionnaire on PD
One-hundred fifty-eight copies of the Dutch question-
naire were completed and returned. One-hundred seven
of those returned, 56 males (17 neutered) and 61
females (49 neutered), met the inclusion criteria for the
affected state. Ninety-six of the included dogs were
Dutch and 4 came from Germany. Additionally, ques-
tionnaires about affected Border Terriers from Belgium
(3), the United Kingdom (3), and Switzerland (1) that
were completed online also were included. The
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population from these countries together is referred to
as the western European population.
In the Finnish survey, 56 questionnaires were com-
pleted, and 40 dogs, 19 females (8 neutered) and 21
males (4 neutered), fulfilled the inclusion criteria.
The median age of onset of clinical signs was 2 years
in the western European dogs and 3 years in the Fin-
nish dogs (range, respectively, from 3 months to 9 years
and from 6 months to 6 years). Of the western Euro-
pean dogs, 17% had ≥1 episodes per week, 9% had epi-
sodes every 2–3 weeks, 6% every 4–5 weeks, and 8%
every 6–7 weeks. The majority of dogs (57%) had an
episode frequency of less than once every 7 weeks. The
median number of episodes in the Finnish population
was 7 per year. The yearly number ranged from 1 to
approximately 200 in both populations.
The majority of Finnish owners (58%) noticed that
their dogs were prone to episodes in particular situa-
tions or emotional states, whereas 40% of the western
European owners observed predisposing factors. Typical
situations or emotional states preceding episodes
included physical exercise (20%), stress (16%), agitation
(7%), hot weather (5%), and loud noise or bright lights
(3%). Conversely, 16% of owners of affected Border
Terriers reported that episodes usually occurred during
rest or sleep.
Of the western European and Finnish owners, respec-
tively, 69% and 44%, noticed signs preceding the epi-
sodes in their dogs. The most typical signs were
attention seeking and restlessness in both groups. Other
signs before the episodes included withdrawing, a stiff
gait, freezing (ie, stiffening and not moving), absent-
mindedness, staring, panting, fear, perceived nausea,
vomiting, and salivating. The duration of the phase
with the above-mentioned signs varied markedly
between 30 second and 48 hour (median, 5 minutes,
only recorded in the western European dogs).
The median duration of episodes was 5 minutes in
the western European and 4.5 minutes in the Finnish
dogs (respective ranges, 5 seconds–90 minutes and
30 seconds–50 minutes). Nineteen percent of the west-
ern European and 23% of Finnish cases experienced >1
episode within 24 hour.
Clinical features were comparable between the west-
ern European and Finnish cases. The most typical signs
that occurred always or often during an episode were
dystonia of limbs, back, neck or some combination of
these (78% and 85%, respectively), muscle fascicula-
tions (76% and 76%, respectively), and falling over
(65% and 69%, respectively). Autonomic signs were
noticed in some dogs, in particular salivating (31% and
32%, respectively), borborygmi (22%, only recorded in
the western European dogs), and involuntary urination
(14% and 16%, respectively). Other reported signs in
order of frequency were ataxia, muscle spasms of the
limbs, neck or both, attention seeking, licking and bit-
ing-type movements, fear, bumping into things, and
facial muscle twitching. Most owners believed that con-
sciousness was not lost during episodes (85% and 73%,
respectively), or were not able to assess consciousness
(13% and 7%, respectively). Sixty-one percent of the
owners from western Europe reported that their dogs
clearly responded if spoken to or touched during an
episode.
In the western European population, 68% of affected
dogs showed clinical signs after an episode. The dura-
tion of this phase ranged between 1 minute and 48 hour
(mean, 30 minutes). Eighty-four percent of the affected
Finnish dogs recovered from the episode within 15 min-
utes. The most common signs after an episode were
lethargy (33%), being affectionate (24%), confusion
(16%), withdrawal (12%), restlessness (9%), fear (9%),
perceived nausea (5%), and thirst (5%) in both groups.
Twenty-five percent of Finnish dogs (10/40) were
receiving anti-epileptic medication. Eighty percent of
them (8/10) were being treated with PO phenobarbital,
and 20% (2/10) with PO phenobarbital in combination
with potassium bromide. Anti-epileptic medication had
immediately and completely stopped episodes in 30% of
dogs (3/10). The medication had been helpful for all
treated Finnish dogs, resulting in milder clinical signs, a
decrease in episode frequency, shortening of the recov-
ery time, or some combinations of these.
Medication for PD was given in 38% (41/107) of the
affected western European dogs. The most frequently
prescribed medications were phenobarbital (21%, 22/
107: 2 single injections and 20 PO medication), diaze-
pam (9%, 10/107: 3 single injections, 5 suppository, and
4 PO medication), butylscopolamine (7%, 7/107: 1 sin-
gle injection, 6 suppository) and glucocorticoids (7%, 7/
107: 2 single injections, 5 PO medication). Half of the
owners of dogs on phenobarbital therapy (11/22)
assessed the response to treatment as reasonable or
good. Diazepam by suppository resulted in reasonable
control of clinical signs in all cases (5/5). Outcome of
PO diazepam treatment was reasonable in 75% (3/4) of
treated cases. Intravenous injection of diazepam
stopped episodes in 66% of cases (2/3). Butylscopo-
lamine had a reasonable to good effect in 57% of
patients (4/7). In the remaining 43% (3/7), however, it
had no beneficial effect at all. Owners reported a good
to reasonable response to therapy in 57% (4/7) of dogs
treated with glucocorticoids. The other 43% (3/7) did
not experience amelioration of signs by any means.
Response to therapy could include all of the following:
a decrease in frequency, milder clinical signs, and short-
ening of the duration of the episode.
Thirty-six percent (39/107) of the owners from west-
ern Europe changed the diet because of the episodes. In
79% (31/39) of these cases, a reasonable or good
improvement of clinical signs was observed. In all of
these cases (31/31), episode frequency decreased, in
35% (11/31) manifestations during episodes were milder
and in 26% (8/31) the duration of the episodes
decreased. The new diets used were very variable, but in
38% (15/39) of cases, the diet was changed to a hypoal-
lergenic (in all cases gluten-free) diet. All of these dogs
previously had received commercial maintenance food
or a mixture of foods. In 73% (11/15) of cases that
were switched to a hypoallergenic diet, it could be con-
firmed that the former diet contained gluten. In the
remaining cases, an exact list of ingredients of the diet
1126 Stassen et al
was not available, but the diet was considered unlikely
to be gluten-free, because most owners combined sev-
eral foods. All dogs receiving hypoallergenic diets
showed reasonable (40%, 6/15) or good (60%, 9/15)
improvement of clinical signs after dietary change.
Clinical Studies
General physical examination and neurological exam-
ination identified no clinically relevant abnormalities in
all 35 affected dogs examined, nor in the 7 healthy con-
trols. One affected dog showed slightly decreased postu-
ral reactions in the right pelvic limb, which was
considered to be an unrelated problem. Complete blood
count and biochemical profile results were within refer-
ence intervals except for some slight and inconsistent
abnormalities in both groups. Alkaline phosphatase
activity was mildly increased (highest activity 257 U/L)
in 5 of 35 affected dogs. However, 3 of them had been
treated with phenobarbital, a drug known to increase
total alkaline phosphatase activity.22 All of them had
fasting serum bile acid and ammonia concentrations
within reference intervals.
Magnetic resonance or CT imaging of the brains of
17 affected Border Terriers and 7 healthy controls was
unremarkable. No abnormal activity was detected on
EEGs recorded between episodes in 10 affected and 7
healthy control Border Terriers.
Pedigree Analysis
Inspection of pedigrees of affected western European
and Finnish Border Terriers showed a high prevalence
of cases in specific lines, whereas other lines were free
of disease. Most cases had healthy parents and, in
approximately half of the affected litters, >1 individual
was affected (Figs 1 and S1). Because the health status
of a large number of parents and siblings of affected
dogs could not be confirmed, we could not perform seg-
regation analysis to determine the most likely mode of
inheritance.
Genetic Studies
We performed a GWAS with 238 ascertained cases
and controls to detect chromosome regions that could
harbor genes involved in PD. A total of 104,079 SNPs
passed quality control. The multidimensional scaling
plot showed an even distribution of cases and controls
in the sample, indicating that there were no large differ-
ences in the genetic background of the case and control
groups (Fig 2). However, the genomic inflation factor
was found to be high (k = 1.8), meaning that marker
alleles were in general not distributed evenly over the
dogs in the sample as a consequence of population





Fig 1. Typical pedigree of 76 western European Border Terriers segregating PD. The trait is often seen in littermates and half-siblings.
Black symbols: affected; nonfilled symbols: unaffected. Squares: males; circles: females; diamonds with numbers: number of male and
female unaffected littermates (status based on questionnaires and breeder reports). *Full siblings from multiple litters.
Fig 2. Multidimensional scaling plot based on DNA data of indi-
vidual Border Terriers. A principal component analysis of the
SNP data of the dogs was performed with GenABEL software.
Red dots represent western European cases, orange dots Finnish
cases, green dots western European control dogs, and blue dots
Finnish control dogs. Within each population, cases and controls
are similarly distributed in the plot.
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inflation factor. No chromosome regions with signifi-
cant association to the disorder were observed. A clus-
ter analysis whereby the sample was divided into
geographic subgroups did not alter this result. A weak
association, after correcting for data stratification and
multiple testing by a permutation procedure, was found
on chromosome 2 (BICF2P455713: P = .24, Fig 3).
Notably, no association whatsoever with the regions of
the genome containing genes related to PDs in humans
(PNKD, KCNMA1, PRRT2 and SLC2A1) was detected.
Mean inbreeding coefficients (SD) were
0.034  0.097 and 0.012  0.061 for cases and controls,
respectively. A Student’s t-test was performed and indi-
cated that the difference between cases and controls was
significant (P = .042).
Discussion
Epidemiological, clinical, and genetic studies of dogs
with epilepsy and episodic movement disorders are ham-
pered by difficulty in correctly diagnosing and classifying
them. Because neurological examination between epi-
sodes usually is normal, the clinician or researcher is reli-
ant primarily on the descriptions of attacks by owners,
who may be biased or may misinterpret signs. Attacks
may not be recognized or may be missed during the
night or in the absence of the owner. Furthermore, even
for an experienced neurologist, it can be difficult to dif-
ferentiate among atypical focal epileptic seizures, parox-
ysmal dyskinesias, and other paroxysmal disorders
without further diagnostics such as ictal EEG recordings.
Another challenge in describing a newly recognized
syndrome with variable phenotype is to assess whether
less common signs are part of the phenotypic variation
or represent another disorder of independent etiology.
Hence, formulating inclusion and exclusion criteria can
be difficult, and one should be careful to avoid circular
reasoning. For example, in 1 study dogs that displayed
autonomic signs such as urination, defecation, and sali-
vation during episodes were excluded beforehand.16
Subsequently, in the discussion, it was concluded that
these autonomic signs were consistently absent in
CECS, which was used as an argument against cramp-
ing episodes being an epileptic disorder. Border Terriers
with other autonomic signs such as borborygmi or vom-
iting related to the episodes were not excluded.
Here, we used broad inclusion criteria for enrollment
in the PD questionnaire study, and characteristic signs
were defined afterward based on the results. Therefore,
we cannot rule out the possibility that some dogs ini-
tially included suffered from other disorders such as
idiopathic epilepsy. However, most exhibited a pheno-
type that was distinctly different from that of typical
idiopathic epilepsy (eg, only 2% of the western Euro-
pean owners reported loss of consciousness during epi-
sodes). For the genetic studies, inclusion criteria were
refined based on the outcome of the questionnaires to
select the most typical cases.
Clinical characteristics reported in the western Euro-
pean and Finnish populations of Border Terriers with
PD generally were comparable. The episode phe-
nomenology, severity of signs, and frequency of epi-
sodes, however, varied considerably among individual
dogs. However, consciousness was consistently unim-
paired during the episodes in most cases. Results of
clinical examinations, blood testing, and diagnostic
imaging generally were unremarkable.
The clinical features reported here are mostly similar
to those described previously in smaller groups of Ger-
man and British Border Terriers.16,23 Therefore, we con-
clude that these populations most likely suffer from the
same condition. Recently, comparable syndromes have
been described in Norwich Terriers24 and in a young
Yorkshire Terrier.25
It has been postulated that the CECS phenotype is
suggestive of PD rather than focal epilepsy.16 The combi-
nation of preserved consciousness and dystonia of all
limbs during episodes as encountered in many affected
Border Terriers is a strong indication for this distinction.
In addition, epileptic seizures in dogs usually are brief
(most last <3 minutes26), whereas episodes of PD often
last >5 minutes and episodes of >2 hours were reported.
The lack of abnormalities on EEG recordings
between episodes in our study strongly supports the
diagnosis of PD. Abnormal interictal activity on EEG
recordings has been identified in 25–65% of dogs with a
clinically established diagnosis of epilepsy,27,28 whereas
an abnormal EEG is rare in PDs.9 In our study, none
of the 10 affected Border Terriers that were investigated
using EEG between episodes had abnormal EEG
recordings, making epilepsy unlikely. Unfortunately, we
were not able to perform EEG recordings during epi-
sodes, and thus confirm with greater certainty that the
episodes were not epileptic seizures.
Fig 3. Genomewide association study of PD in Border terriers.
The allele frequencies of SNPs across the genome were compared
in the groups of cases and controls and corrected for population
stratification and for multiple testing by permutations of the phe-
notype in the data set. The results are depicted for all chromo-
somes in alternating colors.
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The presence of a phase with clinical signs directly
after the episodes in the majority of affected Border
Terriers and autonomic signs in some are less typical
for PD as described in humans. Nevertheless, based on
the considerations described above, focal epilepsy is less
likely and the term CECS can be replaced by the
descriptive term PD, which refers to a group of move-
ment disorders characterized by recurrent episodes of
hyperkinesia, altered muscle tone, or both.
In humans, PDs are categorized primarily based on
precipitating events. Because episodes in Border Terriers
are not typically triggered by sudden movement or pro-
longed exercise, they are most consistent with paroxys-
mal nonkinesigenic dyskinesia (PNKD).
The debate about the pathophysiology of PD is
ongoing, but neurophysiological and functional imaging
studies suggest a major role for the basal nuclei and
related structures.9,29,30 Some authors suggest that PKD
is a form of subcortical epilepsy involving the basal
nuclei and their connections. This is further supported
by the finding that lesions of the basal nuclei can result
in secondary PKD.9 As in human patients with primary
PD, no abnormalities were detected in the region of the
basal nuclei during diagnostic imaging of the brains of
affected Border Terriers.
In contrast to previous reports, most owners of Bor-
der Terriers treated with anti-epileptic drugs, especially
phenobarbital and diazepam, judged the therapy to be
beneficial. However, the different dosages and treatment
protocols used make it difficult to draw meaningful con-
clusions. Furthermore, a substantial placebo effect,
manifested as a decrease in seizure frequency, has been
identified in epilepsy treatment trials in dogs.31 This
probably also is applicable to other paroxysmal disor-
ders. Consequently, to evaluate the efficacy of medical
treatment on PD in Border Terriers, prospective dou-
ble-blind placebo-controlled studies are required.
A beneficial effect of anticonvulsant therapy also has
been reported in PD in humans.30,32 Especially, PKD
responds dramatically to anti-epileptic drugs, even at low
dosages. In PNKD, a favorable response to benzodi-
azepines is observed in some cases. An episodic move-
ment disorder in a German Shorthaired Pointer
responded well to low dosages of both phenobarbital and
potassium bromide.12
Most owners who changed the diets of their affected
Border Terriers stated that doing so resulted in reason-
able to good improvement of clinical signs. In dogs that
were changed to a commercial hypoallergenic diet (in
all cases gluten-free), a reasonable to good effect was
noted in all cases. A favorable effect of dietary change
also was observed in another study.16 Although the
above-mentioned placebo effect might have resulted in
overstating the beneficial effect of the hypoallergenic
diet, there are strong indications that diet influences the
clinical course of the disease.
In human medicine, neurological manifestations
including cerebellar ataxia, myoclonus, chorea, and epi-
lepsy have been reported in 22.5–51% of patients with
celiac disease (CD).33,34 Celiac disease is a multisystem
immune-mediated disorder triggered by the ingestion of
gluten, predominantly causing gastrointestinal clinical
signs. However, neurological signs without enteropathy
are increasingly recognized.35 Genetic factors play an
important role in the development of CD. A girl with
confirmed CD and a movement disorder resembling
PNKD has been reported.36 Neurological clinical signs
completely resolved after introduction of a gluten-free
diet. Recently, increased concentrations of antitransglu-
taminase and antigliadin antibodies were identified in
the serum of 6 Border Terriers with CECS.37 A strict
gluten-free diet resulted in clinical and serological
improvement in all dogs. It was concluded that CECS
in Border Terriers is a gluten-sensitive condition, trig-
gered and perpetuated by gluten.
It seems plausible that the significantly higher
inbreeding coefficients in PD cases compared to controls
observed in our study reflect an underlying genetic
cause. Additionally, pedigree analysis identified an
increased prevalence of affected dogs in specific families
of Border Terriers. Together with the observation that
PD occurs almost exclusively in Border Terriers, these
findings indicate an inherited disorder.
The selection for dog breeds in the past few centuries
resulted in a unique population structure, with high
levels of genetic homogeneity within breeds. This situa-
tion greatly facilitates studies that attempt to unravel
the genetic background of inherited diseases.38,39 Geno-
mewide association studies aim to identify genetic mark-
ers that are associated with a specific phenotype in
order to map disease-causing genes. In dogs, GWAS is a
powerful tool to identify loci of monogenic traits in rela-
tively small numbers of cases and controls.14,15,40 For
instance, a GWAS of 5 cases and 8 controls sufficed to
localize the gene for episodic falling syndrome in Cavalier
King Charles Spaniels.14 Another GWAS of 23 cases and
37 controls effectively mapped the gene for dispropor-
tionate dwarfism in Labrador retrievers.41 According to a
study of modeling in dogs,42 the power of our GWAS to
detect a locus with dominant inheritance was at least
99%, whereas the power to detect a locus that multiplies
the relative risk of the phenotype 5-fold was 97%.
Failure to achieve conclusive results in a GWAS of a
cohort of 110 cases and 128 controls with a large infor-
mative set of SNPs suggests that inheritance of PD in
Border Terriers likely is complex. Furthermore, the
marked variety in clinical presentation among cases fur-
ther supports a complex mode of inheritance. Addi-
tional studies to elucidate the genetic background are
required and could involve whole genome sequencing in
well-characterized pedigree samples.
In conclusion, the presented survey and EEG studies
provide further evidence that the studied syndrome in
Border Terriers is a PD rather than epilepsy. Our
genetic studies suggest that PD probably is a disorder
with complex inheritance.
Footnotes
a Magnetom Open Viva, Siemens N.V., The Hague, The Netherlands
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b Dotarem (376.9 mg/mL gadoterate meglumine), Guerbet, Roissy
CdG Cedex, France
c Siemens Magnetom Symphony, 1.5T, Siemens AG, Medizinische
Technik, Germany
d Magnevist (469 mg/mL inject. gadopentetate dimeglumine),
Schering AG, Berlin, Germany
e Somatom Emotion Duo; Siemens AG, Forchheim, Germany
f Iomeron (71.44% w/v of iomeprol, equivalent to iodine 350 mg/mL),
Bracco, High Wycombe, United Kingdom
g Domitor (1 mg/mL, medetomidine hydrochloride), Orion
Pharma, Espoo, Finland
h Microsoft Excel (version 2010, t-test: two-sample assuming equal
variances)
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Figure S1. Pedigree of Finnish Border Terriers segre-
gating PD. Black symbols: affected; nonfilled symbols:
unaffected. Squares: males; circles: females.
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